Concepedia

Mark T. Jay

MT

Statistics

Publications

3

Citations

192

H-Index

3

Active since

2003

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

MSD (UK) Limited (United Kingdom)

Mark T. Jay is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in pharmacology, neuroscience, and neuropharmacology.

Publications per year

2003–2006

3

Publications

3

Quantitative Measurement of Changes in Amyloid-β(40) in the Rat Brain and Cerebrospinal Fluid following Treatment with the γ-Secretase Inhibitor LY-411575 [N2-[(2 S)-2-(3,5-Difluorophenyl)-2-hydroxyethanoyl]-N1-[(7 S)-5-methyl-6-oxo-6,7-dihydro-5 H-dibenzo[b,d]azepin-7-yl]-l-alaninamide]

Jonathan D. Best, Mark T. Jay, Franklin Otu et al. · Journal of Pharmacology and Experimental Therapeutics · 2005 · 98 citations

, , +14

In Vivo Characterization of Aβ(40) Changes in Brain and Cerebrospinal Fluid Using the Novel γ-Secretase Inhibitor N-[cis-4-[(4-Chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethanesulfonamide (MRK-560) in the Rat

Jonathan D. Best, Mark T. Jay, Franklin Otu et al. · Journal of Pharmacology and Experimental Therapeutics · 2006 · 64 citations

, , +17

Stress-induced increase of cortical dopamine metabolism: attenuation by a tachykinin NK1 receptor antagonist

Peter H. Hutson, Shil Patel, Mark T. Jay et al. · European Journal of Pharmacology · 2003 · 30 citations

, , +16

1–3 of 3